Biotech / MedicalNNBP - Nanobac Pharmaceuticals Inc. (Bulls Board)

Previous 10 Next 10 
To: donpat who wrote (34)9/28/2006 12:03:10 PM
From: donpat
   of 106
Email answer:

Dear (me),

Unfortunately the book is sold out. Though an update is plan a new publication date has not been set.

Your team

Share RecommendKeepReplyMark as Last Read

From: donpat9/28/2006 3:27:51 PM
   of 106
Are Nanobacteria Making Us Ill?

By Amit Asaravala| Also by this reporter
02:00 AM Mar, 14, 2005

Olavi Kajander didn't mean to discover the mysterious particles that have been called the most primitive organisms on Earth and that could be responsible for a series of painful and sometimes fatal illnesses.

He was simply trying to find out why certain cultures of mammalian cells in his lab would die no matter how carefully he prepared them.

So the Finnish biochemist and his colleagues slipped some of their old cultures under an electron microscope one day in 1988 and took a closer look. That's when they saw the particles. Like bacteria but an astonishing 100 times smaller, they seemed to be thriving inside the dying cells.

Believing them to be a possible new form of life, Kajander named the particles "nanobacteria," published a paper outlining his findings and spurred one of the biggest controversies in modern microbiology.

At the heart of the debate is the question of whether nanobacteria could actually be a new form of life. To this day, critics argue that a particle just 20 to 200 nanometers in diameter can't possibly harbor the components necessary to sustain life. The particles are also incredibly resistant to heat and other methods that would normally kill bacteria, which makes some scientists wonder if they might be an unusual form of crystal rather than organisms.

In 1998, Kajander tried to prove the skeptics wrong by turning up what he believed to be an example of nanobacteria's ribosomal RNA, something that only organisms have. But the claim was squashed two years later by a National Institutes of Health study, which found that the RNA was actually a remnant from a type of bacteria that often contaminates lab equipment.

The debate would have ended there, except for a steadily increasing number of studies linking nanobacteria to serious health problems, including kidney stones, aneurysms and ovarian cancer. The studies show that nanobacteria can infect humans, a find that has helped push nanobacteria back into the limelight. Now the pressure is on to resolve the controversy and expose how nanobacteria works -- no matter what it is.

"It's all pretty exciting stuff," said David McKay, chief scientist for astrobiology at NASA's Johnson Space Center. "Whether these are bacteria or not -- it doesn't matter at this point. What matters is if we can figure out the association between nanobacteria and kidney stones and develop some kind of countermeasure."

The link between nanobacteria and human diseases was first noticed by Kajander and microbiologist Neva Çiftçioglu in 1998. The researchers had observed, through an electron microscope, nanobacteria particles building shells of calcium phosphate around themselves. They began to investigate whether such particles played a role in causing kidney stones, which are also made of calcium compounds. Sure enough, at the center of several stones was a nanobacteria particle.

Another breakthrough came in 2003 when a team from the University of Vienna Medical Center discovered nanobacteria in the calcified debris found in tissue samples from ovarian cancer patients. Meanwhile, several other studies revealed nanobacteria in samples of calcified arteries.

Sensing a growing need for tools to detect and study nanobacteria, Kajander and Çiftçioglu formed a company called NanoBac in 1998. The decision was greatly criticized as a conflict of interest and is still brought up whenever either of the two publishes a new paper.

Fortunately for the researchers, a 2004 study by the esteemed Mayo Clinic supported many of their key findings and helped them regain some of their support. The Mayo study found that nanobacteria do indeed self-replicate, as Kajander had noticed, and endorsed the idea that the particles are life forms.

Kajander and Çiftçioglu were further vindicated this February when patients with chronic pelvic pain -- thought to be linked to urinary stones and prostate calcification -- reported "significant improvement" after using an experimental treatment provided by Nanobac Life Sciences, which now owns NanoBac. The study was conducted by a team at Cleveland Clinic Florida.

There's a lot riding on studies like these. Roughly 177,500 patients were discharged from U.S. hospitals with kidney stones and related problems in 2001, according to the NIH. More than 25,000 women in the United States are diagnosed with ovarian cancer each year. In the same period, 14,000 Americans die from complications caused by calcified arteries.

"It brings up a lot of questions," said John Lieske, who led the 2004 Mayo Clinic study. "How many kidney stones are caused by this? Are there other calcification-related diseases that are caused by nanobacteria? Is it infectious?"

Surprisingly, few groups are actually working on answering these questions. One would be hard-pressed to find more than a half-dozen research teams around the globe studying nanobacteria full time.

Lieske suggests it's because the field is still relatively young. But it's clear that there's an additional culprit: the often heated controversy over whether nanobacteria particles are, in fact, alive.

"There's a reluctance to get into controversial areas. It's hard to get proposals funded," said McKay. "Most people are waiting until there's a little more meat on the bones."

Even John Cisar, who led the 2000 NIH study that contradicted Kajander's initial findings, agrees that the issue has become muddled. Though he maintains his stance that nanobacteria are not alive, he said in a phone interview that he is not against further research.

"I'm not saying there's nothing there," said Cisar. "It's just that we were looking at it from a microbiologist's perspective. And when we didn't find any signs of life, we moved on."

Kajander stands by his original assertion that nanobacteria are life forms. However, he blames himself for getting researchers hung up on the life question by using the name "nanobacteria."

"Calcifying self-propagating nanoparticles would have been much better," he wrote in an e-mail to Wired News.

But he added that his regrets about the name don't change the fact that nanobacteria have "miraculous" properties. Those include a growth cycle that closely matches typical biological cycles, the ability to form a shell and the "presence of both mammalian and bacterial components."

It's these properties -- and the potential to save lives -- that keep researchers focused on nanobacteria.

In February, NASA's McKay and Nanobac's Çiftçioglu announced that they had observed nanobacteria growing at five times its normal rate after they placed it in an incubator that simulates the microgravity conditions of space. The findings mean astronauts may be at an elevated risk for kidney stones on long flights -- something NASA is extremely worried about in light of its new plans to send humans to Mars.

The findings could also add fuel to nanobacteria research by giving scientists a way to grow cultures faster.

"The trouble with studying nanobacteria is that trying to get enough material is very hard," said Lieske. "Trying to culture a lot of it takes time."

Indeed, nanobacteria particles double about once every three days. In comparison, typical bacteria double about every 20 minutes.

Lieske's group has continued to experiment with nanobacteria since its 2004 paper. Though he said the team is looking for evidence of DNA and RNA, he is cautious about saying whether he thinks the particles are alive or just an unknown form of crystal.

As a possibility, he offered a third option: The particles could be a form of archaea, a relatively new category of tiny organisms whose DNA is vastly different from that found in typical bacteria. Over the past two decades, archaea have surprised scientists by turning up in places where life was least expected, like in sulfurous lakes and hydrothermal sea vents.

Whatever the case, the Mayo Clinic team may publish a paper outlining new findings in about six months, according to Lieske.

The world may not be waiting, but a handful of faithful microbiologists certainly will.

Share RecommendKeepReplyMark as Last Read

From: donpat10/4/2006 10:34:35 AM
   of 106
Nanobac Pharmaceuticals Inc. Signs Agreement with American Health Associates Clinical Laboratories to Provide Calcifying Nanoparticle Tests in the United States

Wednesday October 4, 10:18 am ET

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S.

"Nanobac has partnered with AHA for this important test so that our company can focus on its core R&D while continuing to make available and expanding the availability of these tests for research purposes," explained Nanobac Co-Chairman Dr. Benedict Maniscalco. "For the first time ever we now have a qualified laboratory in the U.S. where physicians can send blood samples for testing, along with authorized stations where patients can go to have blood drawn and know that the samples will be properly handled," Dr. Maniscalco added.

The tests can detect CNP antigens and antibodies. Analysis is done by Nanobac's own laboratories in Kuopio Finland; the only lab in the world capable of such analysis. Nanobac has performed thousands of such tests worldwide since the year 2000.

(a) (Note to editors: the term "Calcifying Nanoparticle (CNP)" has been adopted in recently published literature to help distinguish these particles from bacteria.)

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria." The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: .

Nanobac Pharmaceuticals, Tampa
Benedict Maniscalco, 813-264-2241
American Health Associates Clinical Laboratories
Debbie Martin, 305-984-5023
Redwood Consultants
Jens Dalsgaard, 415-884-0348

Share RecommendKeepReplyMark as Last Read

From: donpat10/4/2006 12:36:37 PM
   of 106

NB2 (TM)
Nanobacterial Antigen & Antibody Blood Test


1. Preparation: Fasting is not required.

2. Test Requisition: Fill out Test Requisition in full. A Requesting Physician must be listed.

3. Draw blood: Label 8.0 mL SST (serum separator tube) with permanent marker. Draw blood directly into tube.

4. Tube handling: Invert five times, clot for 30 minutes, centrifuge for 10-15 minutes. Then pour serum off in to a transfer vial. Label transfer vial with permanent marker.

5. Packaging: DO NOT SHIP Serum Separator Tube. Place ONLY the transfer vial containing the serum in a Biohazard safe package for shipping.

6. Shipping: Ship OVERNIGHT EXPRESS Monday through Thursday ONLY to ensure receipt within 24 hours. Patients drawn on Friday: Follow instruction 1-4 and freeze serum at - 20ºC and ship on Monday.

Ship to: 7660 66th Street North, Pinellis Park, FL. 33781
Phone: (727) 541-6588 Fax: (727) 541-6319
Quick link

Share RecommendKeepReplyMark as Last Read

To: jmhollen who wrote (33)10/8/2006 7:37:49 PM
From: ann483
   of 106
jmhollen ? It seems that find you in my stocks that I

buy.. Been buying into "NNBP" over the last 2 weeks..

So now its "DMXP","MRKL,"NNBP"

Also I bought more "MRKL" last week..

Because of Human Emotions

I feel that "NNBP" can shoot to the moon

The Dream stock is "NNBP"

1. Greed Yes All of us want profit..

2. "NNBP" can save MILLIONS OF LIVES..

They are followers is this stock that

think that "NNBB" can be a cure for everything...

[and they could be right]

"NNBP" can go over $15 a share..

Viagra shares went from pennies to dollars in a few weeks

Human Emotions is the key..

IMO Thank you Ann

Share RecommendKeepReplyMark as Last ReadRead Replies (2)

To: ann483 who wrote (40)10/8/2006 8:26:38 PM
From: jmhollen
   of 106
Thanks for the kind words, however, 'donpat' is the one who started this Board and was aware of the company before I noticed it.

Good luck with your investment, our "..Group Watch.." on low priced stocks such as NNVC, SLJB, IPKL, ACHI and others is intended to fill Christmas stockings, increase toy collections, and send kids to college.

John :-)


Share RecommendKeepReplyMark as Last Read

From: donpat10/10/2006 9:34:58 AM
   of 106
WOW!!! No wonder the Mayo Clinic is interested - just look at all the diseases/conditions to be treated:


Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacteriu and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hernodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma. Derrnatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocvtopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type I Diabetes Mellitus. Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications. Cataracts. Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations. Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms,.and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

I'm reminded of the doctor's answer, so often, 'We don't know", when asked 'What causes this?'

Now they WILL know, hopefully!

Share RecommendKeepReplyMark as Last Read

To: ann483 who wrote (40)10/13/2006 5:22:47 PM
From: kirby1111
   of 106
Ann, I agree totally with
your analysis! Once they
validate Koch's postulates for
black pigment gallstones.
the Mayo team proves Koch's
Postulates for atherosclerosis
and releases the data concerning
the DNA/RNA of CNP's/nanobacteria.
The stock will take off! In spite of spirited
discussion of nanobacteria on scientific forums,
there is basically none in the lay media.
This will change and I think the Mayo team
will be the catalyst.
(I understand that the mayo team and
other researchers have deciphered
the genetic information of the organism
but it has not been released to date)
I think what you have here as far as
investors go is people who have done
a lot of research and are holding and those who
purchased because a penny stock
recommendation is posted on on of the
stock boards. Basically the dumb money
and don't have a clue what the co is all about.
How about that Mezo comment that Nanobacteria
are linked in ALL degenerative diseases!!!
This co will change the world in my opinion. Carol

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: kirby1111 who wrote (43)10/18/2006 1:24:04 AM
From: ann483
   of 106
kirby1111 What is so sweet, is all of us are ahead

of the mob.. We have some time..

I will keep buying..

I have been thinking about starting a new board

for only stocks that can go from pennies to over a $1.00

"NNBP" and "AVTX" are two that can do it..

I have other stocks but not like these two..

IMO Thank you Ann

Share RecommendKeepReplyMark as Last ReadRead Replies (2)

To: ann483 who wrote (44)10/18/2006 8:31:01 AM
From: kirby1111
   of 106
Ann, I have never seen a better risk/reward situation
that Nanobac. I was able to retire a single
female in my 40's due to several "high risk"
biotech co's stocks. I purchased them in the early
90's after Hillary care failed and sold in the
late 90's.
There are going to be co's in the future like
Nanobac that have the potential to cure diseases
not just treat symptoms. NNVC is another potential
home run stock. DonPat turned me on to this one.
Let me know where you will be setting up your
discussion group.You are on the right tract!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10 

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.